AbbVie is a research-based biopharma company, developing small molecules and biologics for the treatment of various diseases.
In 2013, Abbott Laboratories splits into two entities- Abbott, Inc., to market medical and diagnostic products and AbbVie, Inc. the research and development focused biopharma company.
- In Feb 2021, AbbVie and Caribou Biosciences signed license agreement to develop allogeneic, “off-the-shelf” CAR-T cell therapies employing Caribou’s next-generation Cas12a CRISPR hybrid RNA-DNA (chRDNA) genome editing and cell therapy technologies to develop two new CAR-T cell therapies directed to targets specified by AbbVie. Under the terms, Caribou received $40 Mn in an upfront cash payment and in equity investment, along with up to $300 Mn in future development, regulatory, and launch milestones.
- AbbVie is responsible for all clinical development, commercialization, and manufacturing efforts and has option to pay a fee to expand the collaboration to include up to an additional two CAR-T cell therapies.
- In Jan 2021, ProBioGen AG has signed a commercial license agreement with AbbVie for applying ProBioGen’s proprietary GlymaxX® technology to boost the antibody-dependent cell-mediated cytotoxicity (ADCC).
- In Dec 2020, Frontier Medicines Corp. and AbbVie signs multi-year collaboration, to utilize Frontier’s proprietary chemoproteomics platform to identify small molecules for programs directed to novel E3 ligases and certain oncology and immunology targets. Under the terms, AbbVie paid Frontier an upfront cash payment of $55 Mn, and is eligible to receive additional milestone payments upto 1 billion USD.
- In Sep 2020, AbbVie and I-Mab (Nasdaq: IMAB) signed collaboration, which provides AbbVie with an exclusive global license, excluding greater China, to develop and commercialize lemzoparlimab (also known as TJC4), anti-CD47 mAb, discovered by I-Mab for the treatment of multiple cancers. Under the terms, AbbVie paidy I-Mab $180 Mn in an upfront payment, along with $20 Mn in a milestone payment based on the Ph I results. In addition, I-Mab will be eligible to receive up to $1.74 billion in success-based milestone payments for lemzoparlimab, of which $840 million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones.
- In June 2020, AbbVie and Genmab entered into a broad collaboration to jointly develop and commercialize three of Genmab’s next-generation bispecific antibody products, including epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4. AbbVie paid Genmab an upfront payment of USD 750 Mn with total potential milestone payments of up to USD 3.15 billion.
- In June 2020, Abbvie acquired exclusive license to develop and commercialize Jacobio’s SHP2 inhibitors JAB-3068 and JAB-3312 against cancer from Jacobio Pharmaceuticals Co. Ltd. Under the terms, AbbVie will be granted an exclusive license to the Jacobio’s SHP2 portfolio. Jacobio will continue to conduct early global clinical trials of JAB-3068 and JAB-3312 with AbbVie covering R&D expenses. Upon completion, AbbVie will assume global development and commercialization responsibilities. Jacobio has an option, to exclusively develop and commercialize the SHP2 program in Greater China region. Financial terms remains undisclosed.
- In Nov 2019, AbbVie (NYSE: ABBV) signed multi-target research collaboration, to advance a number of Dragonfly’s novel NK cell engager-based immunotherapies developed using Dragonfly’s TriNKET™ technology platform for autoimmune and oncology indications. Under the terms, AbbVie will pay Dragonfly an upfront payment, future success-based milestone payments and royalties on molecule selection. Further details remains undisclosed.
- In Nov 2019, Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma (planned for IND filing this year). Under the terms, Harpoon will be responsible for development of HPN217 through Ph 1/2 clinical trials. AbbVie may exercise its option to license HPN217 after completion of the Phase 1/2 clinical trial and shall conduct all future clinical development and commercialization activities. The license has a potential transaction value of up to $510 Mn in upfront, option and milestone payments, plus royalties on global commercial sales.
- Earlier in Oct. 2017, AbbVie and Harpoon, entered an immuno-oncology research collaboration, to incorporate Harpoon’s tri-specific T-cell activating construct (TriTAC™) platform with AbbVie’s research-stage immuno-oncology targets to develop novel cancer therapeutics. Under the terms, Harpoon will engineer TriTAC molecules directed against selected cancer targets using its proprietary platform, evaluate the molecules for pharmacologic properties, and provide AbbVie the right to pursue further development and commercialization of these molecules. Financial terms were not disclosed.
- In Sep 2019, Idera entered into an immuno-oncology clinical research collaboration with AbbVie, to conduct a clinical study evaluating combinations of an OX40 agonist (ABBV-368) and a TLR-9 agonist (tilsotolimod). Under the terms of the agreement, Idera will provide clinical trial supply of tilsotolimod to AbbVie and AbbVie will be responsible for conduct of the study.
- In Feb 2019, AbbVie entered a global strategic transaction with Teneobio, Inc. and its affiliate TeneoOne, Inc. to develop and commercialize TNB-383B, a bispecific antibody that simultaneously targets BCMA and CD3, for the potential treatment of multiple myeloma. Under the terms, TeneoOne received an upfront payment of $90 Mn and will continue developing TNB-383B through Phase 1. AbbVie will hold the exclusive right to acquire TeneoOne and lead subsequent global development and commercialization of TNB-383B.
- In Jan 2019, AbbVie and Tizona entered into a global, strategic collaboration to develop and commercialize CD39-targeted therapeutics, including TTX-030, a first-in-class antibody for the treatment of cancer. Under the terms, Tizona received an upfront payment of $105 Mn for the exclusive option to license the CD39 program including TTX-030. In addition, AbbVie has made an equity investment in Tizona. Tizona will lead clinical development through completion of Phase 1b studies, after which AbbVie has an exclusive option to lead global development and commercial activities. Tizona retains an option to co-develop and co-promote in the United States and is eligible for success-based development and commercial milestones and tiered royalties on net sales.
- In June 2018, AbbVie and Calibr, a nonprofit drug discovery division of Scripps Research, signed collaboration to develop T-cell therapies, including solid tumors, utilizing Calibr’s novel switchable CAR-T therapy platform. Under the terms, AbbVie paid Calibr an upfront license fee and gain exclusive access to Calibr’s switchable CAR-T platform for a term of up to four years. The companies to share responsibility for preclinical development, with AbbVie responsible for clinical development and commercialization, and Calibr eligible to receive success-based milestone payments and royalties.
- In Oct 2017, AbbVie and Turnstone Biologics signed a license agreement whereby AbbVie obtained an exclusive option to license up to three of Turnstone’s next-generation oncolytic viral immunotherapies. Financial terms were not disclosed.
- In Apr 2016, AbbVie and CytomX Therapeutics, Inc. (Nasdaq: CTMX) entered into a collaboration to co-develop and co-commercialize Probody™ Drug Conjugates against CD71, also known as transferrin receptor 1 (TfR1). Under the terms, CytomX and AbbVie to co-develop a Probody drug conjugate against CD71, with CytomX leading pre-clinical and early clinical development. AbbVie will lead later development and commercialization, with global late-stage development costs shared between the two companies. CytomX received an upfront payment of $30 Mn and is eligible to receive up to $470 Mn in development, regulatory and commercial milestones, pending the achievement of pre-determined outcomes. AbbVie will lead global commercial activities with CytomX eligible to receive a profit share in the U.S. and tiered double-digit royalties on net product sales outside of the U.S. CytomX retains an option to co-promote in the U.S.
- Under this partnership ABBV-CX-2029 / CX 2029, an antibody-drug conjugate therapeutic directed against CD71, is currently under early clinical development by CytomX (NCT03543813). AbbVie also receives exclusive worldwide rights to develop and commercialize Probody drug conjugates against up to two additional, undisclosed targets.
- In Sep 2014, Infinity Pharmaceuticals and AbbVie entered into a global collaboration to commercialize duvelisib (IPI-145), Infinity’s oral PI3K-delta and PI3K-gamma inhibitor. Under the terms, Infinity received an upfront payment of $275 Mn. In the U.S., the companies will jointly commercialize duvelisib and will share profits equally. Outside the U.S., AbbVie will be responsible commercialization of duvelisib, with Infinity getting double-digit royalties on net product sales.
- In Oct. 2014, Apogenix signed a licensing deal with AbbVie Inc., on a preclinical TNF-related apoptosis-inducing ligand (TRAIL) receptor agonist, APG-880, for various cancer indications.
Page 2 of 3
